Cargando…

Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial

BACKGROUND: Past clinical trials of docosahexaenoic Acid (DHA) supplements for the prevention of Alzheimer's disease (AD) dementia have used lower doses and have been largely negative. We hypothesized that larger doses of DHA are needed for adequate brain bioavailability and that APOE4 is assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Arellanes, Isabella C., Choe, Nicholas, Solomon, Victoria, He, Xulei, Kavin, Brian, Martinez, Ashley E., Kono, Naoko, Buennagel, David P., Hazra, Nalini, Kim, Giselle, D'Orazio, Lina M., McCleary, Carol, Sagare, Abhay, Zlokovic, Berislav V., Hodis, Howard N., Mack, Wendy J., Chui, Helena C., Harrington, Michael G., Braskie, Meredith N., Schneider, Lon S., Yassine, Hussein N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502665/
https://www.ncbi.nlm.nih.gov/pubmed/32690472
http://dx.doi.org/10.1016/j.ebiom.2020.102883
_version_ 1783584247091560448
author Arellanes, Isabella C.
Choe, Nicholas
Solomon, Victoria
He, Xulei
Kavin, Brian
Martinez, Ashley E.
Kono, Naoko
Buennagel, David P.
Hazra, Nalini
Kim, Giselle
D'Orazio, Lina M.
McCleary, Carol
Sagare, Abhay
Zlokovic, Berislav V.
Hodis, Howard N.
Mack, Wendy J.
Chui, Helena C.
Harrington, Michael G.
Braskie, Meredith N.
Schneider, Lon S.
Yassine, Hussein N.
author_facet Arellanes, Isabella C.
Choe, Nicholas
Solomon, Victoria
He, Xulei
Kavin, Brian
Martinez, Ashley E.
Kono, Naoko
Buennagel, David P.
Hazra, Nalini
Kim, Giselle
D'Orazio, Lina M.
McCleary, Carol
Sagare, Abhay
Zlokovic, Berislav V.
Hodis, Howard N.
Mack, Wendy J.
Chui, Helena C.
Harrington, Michael G.
Braskie, Meredith N.
Schneider, Lon S.
Yassine, Hussein N.
author_sort Arellanes, Isabella C.
collection PubMed
description BACKGROUND: Past clinical trials of docosahexaenoic Acid (DHA) supplements for the prevention of Alzheimer's disease (AD) dementia have used lower doses and have been largely negative. We hypothesized that larger doses of DHA are needed for adequate brain bioavailability and that APOE4 is associated with reduced delivery of DHA and eicosapentaenoic acid (EPA) to the brain before the onset of cognitive impairment. METHODS: 33 individuals were provided with a vitamin B complex (1 mg vitamin B12, 100 mg of vitamin B6 and 800 mcg of folic acid per day) and randomized to 2,152 mg of DHA per day or placebo over 6 months. 26 individuals completed both lumbar punctures and MRIs, and 29 completed cognitive assessments at baseline and 6 months. The primary outcome was the change in CSF DHA. Secondary outcomes included changes in CSF EPA levels, MRI hippocampal volume and entorhinal thickness; exploratory outcomes were measures of cognition. FINDINGS: A 28% increase in CSF DHA and 43% increase in CSF EPA were observed in the DHA treatment arm compared to placebo (mean difference for DHA (95% CI): 0.08 µg/mL (0.05, 0.10), p<0.0001; mean difference for EPA: 0.008 µg/mL (0.004, 0.011), p<0.0001). The increase in CSF EPA in non-APOE4 carriers after supplementation was three times greater than APOE4 carriers. The change in brain volumes and cognitive scores did not differ between groups. INTERPRETATION: Dementia prevention trials using omega-3 supplementation doses equal or lower to 1 g per day may have reduced brain effects, particularly in APOE4 carriers. Trial Registration: NCT02541929. FUNDING: HNY was supported by R01AG055770, R01AG054434, R01AG067063 from the National Institute of Aging and NIRG-15-361854 from the Alzheimer's Association, and MGH by the L. K. Whittier Foundation. This work was also supported by P50AG05142 (HCC) from the National Institutes of Health. Funders had no role in study design, data collection, data analysis, interpretation, or writing of the report.
format Online
Article
Text
id pubmed-7502665
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75026652020-09-28 Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial Arellanes, Isabella C. Choe, Nicholas Solomon, Victoria He, Xulei Kavin, Brian Martinez, Ashley E. Kono, Naoko Buennagel, David P. Hazra, Nalini Kim, Giselle D'Orazio, Lina M. McCleary, Carol Sagare, Abhay Zlokovic, Berislav V. Hodis, Howard N. Mack, Wendy J. Chui, Helena C. Harrington, Michael G. Braskie, Meredith N. Schneider, Lon S. Yassine, Hussein N. EBioMedicine Research Paper BACKGROUND: Past clinical trials of docosahexaenoic Acid (DHA) supplements for the prevention of Alzheimer's disease (AD) dementia have used lower doses and have been largely negative. We hypothesized that larger doses of DHA are needed for adequate brain bioavailability and that APOE4 is associated with reduced delivery of DHA and eicosapentaenoic acid (EPA) to the brain before the onset of cognitive impairment. METHODS: 33 individuals were provided with a vitamin B complex (1 mg vitamin B12, 100 mg of vitamin B6 and 800 mcg of folic acid per day) and randomized to 2,152 mg of DHA per day or placebo over 6 months. 26 individuals completed both lumbar punctures and MRIs, and 29 completed cognitive assessments at baseline and 6 months. The primary outcome was the change in CSF DHA. Secondary outcomes included changes in CSF EPA levels, MRI hippocampal volume and entorhinal thickness; exploratory outcomes were measures of cognition. FINDINGS: A 28% increase in CSF DHA and 43% increase in CSF EPA were observed in the DHA treatment arm compared to placebo (mean difference for DHA (95% CI): 0.08 µg/mL (0.05, 0.10), p<0.0001; mean difference for EPA: 0.008 µg/mL (0.004, 0.011), p<0.0001). The increase in CSF EPA in non-APOE4 carriers after supplementation was three times greater than APOE4 carriers. The change in brain volumes and cognitive scores did not differ between groups. INTERPRETATION: Dementia prevention trials using omega-3 supplementation doses equal or lower to 1 g per day may have reduced brain effects, particularly in APOE4 carriers. Trial Registration: NCT02541929. FUNDING: HNY was supported by R01AG055770, R01AG054434, R01AG067063 from the National Institute of Aging and NIRG-15-361854 from the Alzheimer's Association, and MGH by the L. K. Whittier Foundation. This work was also supported by P50AG05142 (HCC) from the National Institutes of Health. Funders had no role in study design, data collection, data analysis, interpretation, or writing of the report. Elsevier 2020-07-17 /pmc/articles/PMC7502665/ /pubmed/32690472 http://dx.doi.org/10.1016/j.ebiom.2020.102883 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Arellanes, Isabella C.
Choe, Nicholas
Solomon, Victoria
He, Xulei
Kavin, Brian
Martinez, Ashley E.
Kono, Naoko
Buennagel, David P.
Hazra, Nalini
Kim, Giselle
D'Orazio, Lina M.
McCleary, Carol
Sagare, Abhay
Zlokovic, Berislav V.
Hodis, Howard N.
Mack, Wendy J.
Chui, Helena C.
Harrington, Michael G.
Braskie, Meredith N.
Schneider, Lon S.
Yassine, Hussein N.
Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial
title Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial
title_full Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial
title_fullStr Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial
title_full_unstemmed Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial
title_short Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial
title_sort brain delivery of supplemental docosahexaenoic acid (dha): a randomized placebo-controlled clinical trial
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7502665/
https://www.ncbi.nlm.nih.gov/pubmed/32690472
http://dx.doi.org/10.1016/j.ebiom.2020.102883
work_keys_str_mv AT arellanesisabellac braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT choenicholas braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT solomonvictoria braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT hexulei braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT kavinbrian braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT martinezashleye braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT kononaoko braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT buennageldavidp braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT hazranalini braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT kimgiselle braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT doraziolinam braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT mcclearycarol braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT sagareabhay braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT zlokovicberislavv braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT hodishowardn braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT mackwendyj braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT chuihelenac braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT harringtonmichaelg braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT braskiemeredithn braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT schneiderlons braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial
AT yassinehusseinn braindeliveryofsupplementaldocosahexaenoicaciddhaarandomizedplacebocontrolledclinicaltrial